We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)


Pursuing a multi-faceted Parsortix commercial opportunity

Outlook | 13 March 2023

Redx Pharma

‘004 mono insufficient in BTC; H223 combo is key

Lighthouse | 08 March 2023


Delivering commercially and strategically during FY22

Lighthouse | 02 March 2023

Redx Pharma

Recommended all share combination with Jounce

Lighthouse | 01 March 2023


Modi-1 successful in first part of Phase I/II trial

Update | 21 February 2023


A leader in antibody and vaccine oncology platforms

Outlook | 15 February 2023

Redx Pharma

RXC007 recruitment scales up; data now Q124

Lighthouse | 09 February 2023

Redx Pharma

Key Phase II data for lead assets expected during H223

Update | 30 January 2023


Takeda licenses fruquintinib in $1.13bn ex-China deal

Lighthouse | 24 January 2023


AVA6000 shows signs of successful tumour targetting

Lighthouse | 17 January 2023
1 2 3 4 5 6 7 8 9 10 >
385 results found.